Skip to content

Bioventus BVS Gain on sale of business and assets

Gain on sale of business and assets at other companies

Avanos Medical logo
Avanos MedicalAVNS

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfBusiness.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's gain on sale of business and assets.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's gain on sale of business and assets?
Bioventus (BVS) reported gain on sale of business and assets of $0 in Q1 2026.
How has Bioventus's gain on sale of business and assets changed year-over-year?
Bioventus's gain on sale of business and assets increased by 100.0% year-over-year, from -$81K to $0.